Resmetirom Dosing Protocol: Complete Prescribing Guide for MASH Treatment

Weight-Based Dosing: 80 mg vs. 100 mg

Resmetirom uses a simple binary weight threshold. Patients weighing less than 100 kg receive one 60 mg tablet plus one 20 mg tablet (totaling 80 mg) each morning. Patients at or above 100 kg take one 100 mg tablet daily. Both doses are taken with food, which increases bioavailability by roughly 25% compared to a fasted state [1].

There is no dose titration, no loading phase, and no renal adjustment. The prescribing label approved by the FDA in March 2024 specifies this fixed weight-based protocol without modification for mild or moderate hepatic impairment [1]. Severe hepatic impairment (Child-Pugh C) was excluded from MAESTRO-NASH, so data in decompensated cirrhosis do not exist.

The 100 kg cutoff was derived from pharmacokinetic modeling in the MAESTRO-NASH population. Body weight significantly affects resmetirom exposure: a 120 kg patient on the 80 mg dose achieves roughly 30% lower area-under-the-curve than a 75 kg patient on the same dose [2]. The 100 mg dose corrects this gap. Clinicians should recheck weight at each follow-up visit and adjust the dose if a patient crosses the threshold in either direction (for example, after bariatric surgery or significant weight gain).

The MAESTRO-NASH Trial: Efficacy Data Behind the Protocol

MAESTRO-NASH enrolled 966 adults with biopsy-confirmed NASH and fibrosis stages F1B through F3 across 200 sites in 14 countries [2]. This is the trial that produced every number on the Rezdiffra label. Participants were randomized 1:1:1 to resmetirom 80 mg, resmetirom 100 mg, or placebo, all taken once daily with food.

At 52 weeks, paired liver biopsies showed two co-primary endpoints met with statistical significance. NASH resolution without worsening of fibrosis occurred in 25.9% of the 80 mg group and 29.9% of the 100 mg group, compared to 9.7% on placebo (P<0.001 for both comparisons) [2]. Fibrosis improvement by at least one stage without worsening of NASH occurred in 25.9% (80 mg) and 24.2% (100 mg), compared to 14.2% on placebo (P<0.001 and P=0.002, respectively) [2].

Both doses also reduced hepatic fat content by MRI-PDFF: a mean decrease of approximately 7 to 8 absolute percentage points at week 52 versus roughly 2 points on placebo [3]. LDL cholesterol dropped 14% in the 80 mg arm and 18% in the 100 mg arm. These lipid effects are consistent with THR-β activation in the liver, which upregulates LDL receptor expression.

The American Association for the Study of Liver Diseases (AASLD) has incorporated resmetirom into its 2024 practice guidance for MASLD/MASH, recommending it as the first-line pharmacotherapy for noncirrhotic patients with significant fibrosis [4].

Administration: Timing, Food, and Missed Doses

Take resmetirom once daily in the morning with a meal or substantial snack. The "with food" requirement is not optional. Fasting reduces drug exposure and may compromise therapeutic efficacy [1]. Any meal composition is acceptable; no specific fat content is required.

If a dose is missed, it should be taken as soon as remembered on the same day. If the missed dose is not remembered until the following day, skip it and resume the regular schedule. Do not double the dose. Consistent daily adherence matters: in MAESTRO-NASH, the median treatment duration was 54 weeks, and the response rate was highest among patients with more than 90% pill adherence [2].

Tablets should be swallowed whole. They should not be crushed, split, or chewed, because the 60 mg and 20 mg tablets used for the 80 mg total dose have different dissolution profiles than the single 100 mg tablet [1].

Drug Interactions and Contraindications

Resmetirom is metabolized primarily through CYP2C8 and CYP3A4 pathways. The one absolute contraindication listed on the label is concurrent use with strong CYP2C8 inhibitors, specifically gemfibrozil, which increases resmetirom exposure approximately threefold [1]. This is a hard stop. Gemfibrozil must be discontinued before starting resmetirom or an alternative fibrate used.

Moderate CYP2C8 inhibitors (clopidogrel, trimethoprim) and strong CYP3A4 inhibitors may also increase exposure, though the label does not contraindicate them outright [1]. Monitor for adverse effects if co-prescribed. Statins are commonly used alongside resmetirom and showed no clinically meaningful interaction in MAESTRO-NASH; in fact, combined LDL reduction was additive [2].

Other considerations for the prescribing clinician:

• Thyroid function: Resmetirom is a selective THR-β agonist that does not activate THR-α (the cardiac isoform). TSH suppression occurred in fewer than 2% of trial participants and was mild [2]. Routine thyroid function testing at baseline and 12 weeks is recommended but not mandated.
• Gallbladder events: Cholelithiasis occurred in 3.4% of resmetirom-treated patients versus 0.9% on placebo in the 52-week dataset [5]. Patients with known gallstone disease require risk-benefit discussion.
• Pregnancy: No human data exist. Animal studies showed fetal harm at supratherapeutic exposures. Resmetirom is not recommended in pregnancy, and effective contraception should be verified in women of reproductive potential [1].

Monitoring on Resmetirom Therapy

Baseline labs before the first dose should include a comprehensive metabolic panel, lipid panel, thyroid function tests (TSH, free T4), and a complete blood count. The FDA label recommends rechecking liver enzymes at 3, 6, and 12 months, then annually [1].

ALT and AST may decrease during therapy. In MAESTRO-NASH, mean ALT fell by approximately 20% from baseline in treated arms versus a 3% decline on placebo at week 52 [2]. This is expected and favorable. A new ALT rise above 3 times the upper limit of normal on therapy warrants investigation: check medication adherence, exclude other hepatotoxins, and consider repeating imaging.

Liver biopsy is the reference standard for assessing histologic response, but routine protocol biopsies are not standard outside clinical trials. Non-invasive surrogates (FibroScan, ELF score, FIB-4 index) may be used to track fibrosis trajectory over 1 to 2 years [4]. The AASLD guidance acknowledges that validated non-invasive response thresholds for resmetirom specifically are still being established [4].

Lipid panels deserve attention at 12-week intervals during the first year, because the LDL-lowering effect may allow statin dose reduction in some patients. Triglycerides also fell modestly in MAESTRO-NASH (approximately 15% reduction), and lipoprotein(a) decreased by roughly 20 to 25% in post-hoc analyses [3]. These cardiometabolic benefits extend the therapeutic value beyond the liver.

Vitamin E Dosing in NASH: An Alternative Protocol

Before resmetirom, vitamin E at 800 IU per day was the only pharmacotherapy with positive biopsy data for NASH. The PIVENS trial (N=247) randomized adults with nondiabetic, noncirrhotic NASH to vitamin E 800 IU/day, pioglitazone 30 mg/day, or placebo for 96 weeks [6]. Vitamin E achieved NASH resolution in 36% of patients versus 21% on placebo (P=0.005), though it did not meet the primary composite endpoint that included fibrosis improvement [6].

The AASLD 2023 practice guidance lists vitamin E 800 IU/day as an option for adults with biopsy-confirmed NASH who do not have diabetes or cirrhosis [4]. Two important caveats limit its use in practice. First, the SELECT trial (N=35,533) found that vitamin E 400 IU/day increased prostate cancer incidence by 17% over a median of 5.5 years in healthy men [7]. Whether 800 IU carries even greater risk remains unknown. Second, vitamin E showed no benefit in patients with type 2 diabetes in PIVENS, and since 60 to 70% of MASH patients are diabetic, the eligible population is narrow.

Resmetirom and vitamin E have never been tested head-to-head. The comparative context is worth noting: resmetirom's NASH resolution rate of 26 to 30% at 52 weeks is broadly similar to vitamin E's 36% at 96 weeks, but resmetirom additionally improved fibrosis and has no cancer signal [2][6]. For patients already on vitamin E, the decision to switch or add resmetirom should involve a hepatologist and account for fibrosis stage, diabetes status, and cardiovascular risk.

Special Populations and Off-Label Considerations

Resmetirom is approved only for adults with noncirrhotic MASH at fibrosis stages F2 and F3. Several real-world scenarios fall outside this label.

F1 fibrosis: MAESTRO-NASH enrolled a small F1B subgroup (Brunt criteria), but the FDA approval excluded F1 fibrosis. Off-label use in F1 disease is not currently supported by guideline recommendations [4].

Compensated cirrhosis (F4): Enrollment in MAESTRO-NASH excluded cirrhotic patients. A separate trial, MAESTRO-NASH-OUTCOMES, is evaluating resmetirom in patients with F4 disease and NASH for liver-related clinical events, with results expected in 2028 [8]. Prescribing resmetirom off-label in compensated cirrhosis requires careful documentation and ideally hepatologist oversight.

Pediatric patients: No pediatric data exist for resmetirom. MASH is increasingly diagnosed in adolescents with obesity, but dosing and safety in patients under 18 have not been studied [9].

Concurrent GLP-1 receptor agonists: Many MASH patients use semaglutide or tirzepatide for weight management or type 2 diabetes. No formal interaction study has been published, though mechanistic overlap is unlikely given the distinct receptor targets. A Phase 2 combination trial is underway [10]. In practice, co-prescribing occurs, and no pharmacokinetic red flags have emerged.

Practical Prescribing Checklist

Before writing the first prescription, confirm these steps: biopsy or validated imaging documenting fibrosis stage F2 or F3, documented MASH diagnosis per AASLD criteria, baseline labs (CMP, lipids, TSH, free T4, CBC), and a medication reconciliation specifically checking for gemfibrozil [1]. Weigh the patient and select 80 mg (under 100 kg) or 100 mg (100 kg or above). Counsel on taking the tablet with food every morning. Schedule a follow-up in 12 weeks with repeat liver enzymes and a lipid panel.

The 2024 AASLD guidance recommends reassessing fibrosis trajectory using non-invasive tests at 12 to 24 months and continuing therapy if the patient shows biochemical or imaging improvement [4]. Discontinuation criteria have not been formally defined; MAESTRO-NASH-OUTCOMES data will eventually inform treatment duration. For now, most hepatologists plan to continue resmetirom indefinitely in responders, analogous to statin therapy for cardiovascular risk [4].

Resmetirom 80 mg once daily for patients under 100 kg, 100 mg once daily at or above 100 kg, taken every morning with food: that is the complete dosing protocol as of the current FDA label [1].